<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activating mutations in the fibroblast growth factor receptor 3 (FGFR3) gene are responsible for several <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> syndromes and <z:mp ids='MP_0002657'>chondrodysplasias</z:mp> i.e. hypochondroplasia, <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e>, SADDAN and thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath>--a <z:hpo ids='HP_0003811'>neonatal lethal</z:hpo> <z:hpo ids='HP_0003510'>dwarfism</z:hpo> syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Recently, activating FGFR3 mutations have also been found to be present in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, i.e. at high frequency in <z:mp ids='MP_0002038'>carcinoma</z:mp> of the bladder and rarely in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and <z:mp ids='MP_0002038'>carcinoma</z:mp> of the cervix </plain></SENT>
<SENT sid="2" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> reported mutations in <z:mp ids='MP_0002038'>carcinomas</z:mp> corresponded to the mutations identified in thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>We here screened a series of 297 bladder <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and found three FGFR3 <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> (G380/382R; K650/652M and K650/652T) that were not previously identified in <z:mp ids='MP_0002038'>carcinomas</z:mp> or thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>Another novel finding was the occurrence of two simultaneous FGFR3 mutations in four <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Two of the three new mutations in <z:e sem="disease" ids="C0005684" disease_type="Neoplastic Process" abbrv="">bladder cancer</z:e>, the G380/382R and the K650/652M mutations, were previously reported in <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> and SADDAN, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>These syndromes entail a longer life span than thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="7" pm="."><plain>The K650/652T mutation has not previously been detected in patients with <z:e sem="disease" ids="C0263661" disease_type="Disease or Syndrome" abbrv="">skeletal disorders</z:e>, but affects a codon that has been shown to be affected in some cases of thanatophoric <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, SADDAN and hypochondroplasia </plain></SENT>
<SENT sid="8" pm="."><plain>From a clinical perspective, the patients with FGFR3-related, non-lethal <z:e sem="disease" ids="C0263661" disease_type="Disease or Syndrome" abbrv="">skeletal disorders</z:e> might be at a higher risk for development of <z:e sem="disease" ids="C0005695" disease_type="Neoplastic Process" abbrv="">bladder tumours</z:e> than the general population </plain></SENT>
</text></document>